FIELD
The present disclosure relates to parasomnias and more specifically to the use of L-tryptophan for the treatment of parasomnias.
INTRODUCTION
Parasomnias are a category of disruptive sleep disorders characterized by the occurrence of abnormal and unwanted movements and behaviours during sleep,